EUR 13.54 For Business Accounts Only

CHIN.SHINEWAY PHARM.GLD. increases its risk exposure and slightly lowers to Neutral

CHIN.SHINEWAY PHARM.GLD. (HK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date November 2, 2018, the closing price was HKD 9.88 and its expected value was estimated at HKD 10.37.
China Shineway Pharmaceutical Group (P Chip)

China Shineway Pharmaceutical Group is an investment holding company. Via its subsidiaries, Co. is engaged in the research and development, manufacture and trading of Chinese pharmaceutical products. Co.'s six key products include Qing Kai Ling Injection for treatment of viral diseases including respiratory tract infection, Shen Mai Injection for treatment of coronary heart disease, Shu Xie Ning Injection for treatment of cardio-cerebrovascular disease, Wu Fu Xin Nao Qing Soft Capsule for treatment of coronary heart disease, Huo Xiang Zheng Qi Soft Capsule for prevention and treatment of heat stroke,and Pediatric Qing Fei Hua Tan Granule for children infected by respiratory related disease.


Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded


Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch